Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline

Alice Chen, Kenneth P. Smith, Betsy A. Whitfield, Paola C. Zucchi, Todd M. Lasco, Tiffany E. Bias, James E. Kirby, Elizabeth B. Hirsch

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

We examined the in vitro activity of minocycline against 103 Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae isolates and found approximately half had susceptible (26%) or intermediate (26%) MICs. For a subset of 35 isolates, susceptibility was highest to tigecycline (71% FDA vs. 20% EUCAST) followed by minocycline (14%) and then doxycycline (6%).

Original languageEnglish (US)
Pages (from-to)365-367
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume88
Issue number4
DOIs
StatePublished - Aug 2017

Keywords

  • Extended-spectrum beta-lactamase
  • KPC
  • Multidrug resistance
  • Resistant
  • Tetracycline

Fingerprint Dive into the research topics of 'Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline'. Together they form a unique fingerprint.

  • Cite this